Initial Statement of Beneficial Ownership (3)

FORM 3	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES	OMB APPROVAL OMB Number: 3235-0104 Estimated average burden hours per response... 0.5
	Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person * Hernandez Alexandra	2. Date of Event Requiring Statement (MM/DD/YYYY) 1/20/2021	3. Issuer Name and Ticker or Trading Symbol Lineage Cell Therapeutics, Inc. [LCTX]
(Last)        (First)        (Middle) C/O LINEAGE CELL THERAPEUTICS, INC., 2173 SALK AVENUE, SUITE 200	4. Relationship of Reporting Person(s) to Issuer (Check all applicable) _____ Director                          _____ 10% Owner ___X___ Officer (give title below)        _____ Other (specify below) Sr Director Finance/Controller /
(Street) CARLSBAD, CA 92008       (City)              (State)              (Zip)	5. If Amendment, Date Original Filed(MM/DD/YYYY)	6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person ___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1.Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security (Instr. 4)	2. Date Exercisable and Expiration Date (MM/DD/YYYY)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (Right to Buy)	(1)	3/17/2030	Common Shares	45200	$0.6919	D
Employee Stock Option (Right to Buy)	(2)	9/1/2029	Common Shares	100000	$0.9000	D

Explanation of Responses:
(1)	One quarter of the options will vest on March 17, 2021 and the remaining will vest in 36 equal monthly installments thereafter upon the completion of each month of continuous employment
(2)	One quarter of the options vested on September 1, 2020 and the remaining will vest in 36 equal monthly installments thereafter upon the completion of each month of continuous employment

Remarks: Exhibit 24.1 - Power of Attorney

Reporting Owners
Reporting Owner Name / Address	Relationships
	Director	10% Owner	Officer	Other
Hernandez Alexandra C/O LINEAGE CELL THERAPEUTICS, INC. 2173 SALK AVENUE, SUITE 200 CARLSBAD, CA 92008			Sr Director Finance/Controller

Signatures
/s/ Chase C. Leavitt, as Attorney-in Fact		1/22/2021
**Signature of Reporting Person		Date